Back to mobile site

Exact Sciences (EXAS) Tops Q2 EPS by 3c, Revs Miss; Maintains Outlook

August 1, 2018 4:09 PM EDT

Exact Sciences (NASDAQ: EXAS) reported Q2 EPS of ($0.30), $0.03 better than the analyst estimate of ($0.33). Revenue for the quarter came in at $102.9 million versus the consensus estimate of $104.66 million.

GUIDANCE:

Exact Sciences sees FY2018 revenue of $420-430 million, versus the consensus of $435.8 million.

For earnings history and earnings-related data on Exact Sciences (EXAS) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Guidance

Related Entities

Earnings